TrialESMO open2026

Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies.

J W Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.